Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial

Journal of Infectious Diseases

Volumn 209, Issue 8, 2014, Pages 1219-1226

  Chou, Sunwen ^a   Boivin, Guy ^b   Ives, Jane ^c   Elston, Robert ^c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b LAVAL UNIVERSITY   (Canada)

^c ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

Antiviral drug resistance; cytomegalovirus; ganciclovir; valganciclovir

Indexed keywords

CIDOFOVIR; DNA POLYMERASE; EXONUCLEASE; FOSCARNET; GANCICLOVIR; VALGANCICLOVIR;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ANTIVIRAL SUSCEPTIBILITY; CONFERENCE PAPER; CONTROLLED STUDY; CYTOMEGALOVIRUS; ENZYME ACTIVE SITE; HUMAN; MUTATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIVIRAL DRUG RESISTANCE; CYTOMEGALOVIRUS; GANCICLOVIR; VALGANCICLOVIR;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, VIRAL; GANCICLOVIR; GENOMIC STRUCTURAL VARIATION; GENOTYPE; HUMANS; MUTATION; PHENOTYPE; POLYMERASE CHAIN REACTION; VIRAL PROTEINS;

EID: 84897438996     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit654     Document Type: Conference Paper

References (20)

1. Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev 2010; 23:689-712.
2. Chevillotte M, Ersing I, Mertens T, von Einem J. Differentiation between polymorphisms and resistance associated mutations in the human cytomegalovirus DNA polymerase. Antimicrob Agents Chemother 2010; 54:5004-11.
3. Chou S, Lurain NS, Weinberg A, Cai GY, Sharma PL, Crumpacker CS. Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories. Antimicrob Agents Chemother 1999; 43:1500-2.
4. Fillet AM, Auray L, Alain S, et al. Natural polymorphism of cytomegalovirus DNA polymerase lies in two nonconserved regions located between domains delta-C and II and between domains III and I. Antimicrob Agents Chemother 2004; 48:1865-8.
5. Hantz S, Garnier-Geoffroy F, Mazeron MC, et al. Drug-resistant cytomegalovirus in transplant recipients: A French cohort study. J Antimicrob Chemother 2010; 65:2628-40.
6. Scott GM, Isaacs MA, Zeng F, Kesson AM, Rawlinson WD. Cytomegalovirus antiviral resistance associated with treatment induced UL97 (protein kinase) and UL54 (DNA polymerase) mutations. J Med Virol 2004; 74:85-93.
7. Asberg A, Humar A, Rollag H, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2007; 7:2106-13.
8. Boivin G, Goyette N, Rollag H, et al. Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. Antivir Ther 2009; 14:697-704.
9. Boivin G, Goyette N, Gilbert C, Humar A, Covington E. Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients. Transpl Infect Dis 2005; 7:166-70.
10. Chou S. Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. Antimicrob Agents Chemother 2010; 54:2371-8.
11. Chou S. Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy. J Clin Virol 2011; 50:287-91.
12. Chou S, Marousek G, Boivin G, et al. Recombinant phenotyping of cytomegalovirus sequence variants detected after 200 or 100 days of valganciclovir prophylaxis. Transplantation 2010; 90:1409-13.
13. Martin M, Gilbert C, Covington E, Boivin G. Characterization of human cytomegalovirus (HCMV) UL97 mutations found in a valganciclovir/oral ganciclovir prophylactic trial by use of a bacterial artificial chromosome containing the HCMV genome. J Infect Dis 2006; 194:579-83.
14. Chou S, Marousek GI, Van Wechel LC, Li S, Weinberg A. Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. Antimicrob Agents Chemother 2007; 51:4160-2.
15. Smith IL, Cherrington JM, Jiles RE, Fuller MD, Freeman WR, Spector SA. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J Infect Dis 1997; 176:69-77.
16. Liu S, Knafels JD, Chang JS, et al. Crystal structure of the herpes simplex virus 1 DNA polymerase. J Biol Chem 2006; 281: 18193-200.
17. Chou S, Van Wechel LC, Lichy HM, Marousek GI. Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene. Antimicrob Agents Chemother 2005; 49:2710-5.
18. Chou S, Ercolani RJ, Marousek G, Bowlin TL. Cytomegalovirus UL97 kinase catalytic domain mutations that confer multi-drug resistance. Antimicrob Agents Chemother 2013; 57:3375-9.
19. Eckle T, Prix L, Jahn G, et al. Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes. Blood 2000; 96:3286-9.
20. Martin M, Goyette N, Boivin G. Contrasting effects on ganciclovir susceptibility and replicative capacity of two mutations at codon 466 of the human cytomegalovirus UL97 gene. J Clin Virol 2010; 49:296-8.